CytoSorbents Faces FDA Setback on Key Drug, Reports Wider Q1 Loss Amid Cash Decline
CTSO is trading near its 52-week low of $0.499 (14% above the low).
Summary
CytoSorbents reported a GAAP net loss of $0.08 per share for Q1 2026, significantly wider than the $0.02 loss in Q1 2025 and worse than analyst expectations of a $0.05 loss, despite adjusted net loss meeting estimates. Revenue saw a modest 2% increase to $8.9 million. Critically, the company's cash and equivalents declined to $6.4 million from $7.8 million, with a cash burn of approximately $1.1 million for the quarter. This continued cash depletion is particularly concerning given the recent 10-K/A filing which highlighted severe financial challenges and going concern warnings due to insufficient liquidity. Furthermore, the company announced a significant regulatory setback for its DrugSorb-ATR® product, with the FDA upholding its prior denial and requesting additional mechanistic data, indicating further delays and hurdles for a key growth driver. The combination of ongoing financial strain and a material regulatory delay for a critical product is likely to weigh heavily on the stock.
At the time of this announcement, CTSO was trading at $0.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.9M. The 52-week trading range was $0.50 to $1.39. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.